Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma

IMPORTANCE: In the IMspire150 trial, triplet treatment with atezolizumab and vemurafenib plus cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib plus cobimetinib alone for treatment of BRAF V600 variation metastatic melanoma. However, considering high cost o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Chao, Yunusa, Ismaeel, Tarhini, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586909/
https://www.ncbi.nlm.nih.gov/pubmed/34762112
http://dx.doi.org/10.1001/jamanetworkopen.2021.32262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586909/
https://www.ncbi.nlm.nih.gov/pubmed/34762112
http://dx.doi.org/10.1001/jamanetworkopen.2021.32262

Ejemplares similares